Shares of Ascendis Pharma A/S (ASND) closed yesterday's trading at an all-time high of $125.29, and that represents a gain of nearly 100% year-to-date.
Shares of Lantheus Holdings Inc. (LNTH) are up an impressive 53% year-to-date, way ahead of the iShares Nasdaq Biotechnology ETF (IBB) index, which has gained only 20% during the same period.
Santa Clara, California-based ShockWave Medical Inc. is a medical device company developing and marketing products based on intravascular lithotripsy (IVL) technology to treat calcified cardiovascular disease.
Shares of Clovis Oncology Inc. (CLVS) are up an impressive 48% year-to-date while the iShares Nasdaq Biotechnology ETF (IBB) index has gained only 19% during the same period.
Kaleido Biosciences is a clinical-stage healthcare company developing microbiome metabolic therapies or MMTs, which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ's existing microbes.
Eton Pharmaceuticals Inc. (ETON), which made its public debut last November, touched a new high of $7.49 yesterday.
Shares of Bausch Health Companies Inc. (BHC), formerly known as Valeant Pharmaceuticals International Inc., are up 35% since the start of this year.
Anchiano Therapeutics, formerly known as Biocancell, is a clinical-stage biotechnology company developing a targeted gene therapy to improve the standard treatment for early-stage bladder cancer.
Shares of BioTelemetry Inc. (BEAT) have been hitting new highs, thanks to the string of strong quarterly results. The stock closed at an all-time high of $76.50 yesterday, and that represents a gain of 30% in just a month.
Harpoon Therapeutics, Inc. is a clinical-stage an immuno-oncology company, and its proprietary antibody-based drug discovery platform is called TriTAC, which offers a new way to unleash the target cell-killing properties of a patient's own immune system.
Shares of Assembly Biosciences Inc. (ASMB) are down nearly 69% from their 52-week high of $67.36 recorded on March 13, 2018.
Shares of AVROBIO Inc. (AVRO) have lost 39% of their value over the last 1 month in sharp contrast to the iShares Nasdaq Biotechnology ETF (IBB) index which has gained 8% during the same period.
Shares of Innoviva Inc. (INVA), which recently touched a new 52-week high of $19.82, are up 12% so far this month, slightly lagging behind the iShares NASDAQ Biotechnology Index (ETF) (IBB), which has gained 14% during the same period.
Axonics Modulation Technologies Inc. (AXNX), which recently made its debut on the NASDAQ, is down nearly 2% so far this month while the iShares Nasdaq Biotechnology ETF index (IBB) has gained nearly 8% for the same period.
Starpharma (SPHRY.OB), on Thursday, announced that it has licensed the sales and marketing rights of VivaGel BV in the United States to ITF Pharma, a subsidiary of Italfarmaco S.p.A, a privately held European specialty pharmaceutical company.